Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 280

1.

Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.

Antonio L, Caerels S, Jardi F, Delaunay E, Vanderschueren D.

Andrology. 2019 May;7(3):302-306. doi: 10.1111/andr.12604. Epub 2019 Mar 8.

PMID:
30851011
2.

Androgen Receptor in Neurons Slows Age-Related Cortical Thinning in Male Mice.

Jardí F, Kim N, Laurent MR, Khalil R, Deboel L, Schollaert D, van Lenthe GH, Decallonne B, Carmeliet G, Claessens F, Vanderschueren D.

J Bone Miner Res. 2019 Mar;34(3):508-519. doi: 10.1002/jbmr.3625. Epub 2019 Jan 15.

PMID:
30496619
3.

In memoriam: Prof. Dr. Guido Verhoeven 26/03/1945-19/08/2018.

Vanderschueren D, Claessens F.

Andrology. 2018 Nov;6(6):810. doi: 10.1111/andr.12560. Epub 2018 Nov 18. No abstract available.

PMID:
30450788
4.

Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study.

David K, Moyson C, Vanderschueren D, Decallonne B.

Eur J Endocrinol. 2019 Jan 1;180(1):71-78. doi: 10.1530/EJE-18-0580.

PMID:
30407920
5.

Free Testosterone Reflects Metabolic as well as Ovarian Disturbances in Subfertile Oligomenorrheic Women.

Antonio L, Pauwels S, Laurent MR, Vanschoubroeck D, Jans I, Billen J, Claessens F, Decallonne B, De Neubourg D, Vermeersch P, Vanderschueren D.

Int J Endocrinol. 2018 Sep 10;2018:7956951. doi: 10.1155/2018/7956951. eCollection 2018.

6.

Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS.

Rastrelli G, O'Neill TW, Ahern T, Bártfai G, Casanueva FF, Forti G, Keevil B, Giwercman A, Han TS, Slowikowska-Hilczer J, Lean MEJ, Pendleton N, Punab M, Antonio L, Tournoy J, Vanderschueren D, Maggi M, Huhtaniemi IT, Wu FCW; EMAS study group.

Clin Endocrinol (Oxf). 2018 Oct;89(4):459-469. doi: 10.1111/cen.13756. Epub 2018 Jul 23.

PMID:
29855071
7.

Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.

Bastin J, Werbrouck E, Verbiest A, Punie K, Bechter O, Woei-A-Jin FJ, Wolter P, Wildiers H, Lerut E, Dumez H, Decallonne B, Clement P, Vanderschueren D, Albersen M, Oyen R, Schöffski P, Beuselinck B.

Acta Clin Belg. 2019 Jun;74(3):169-179. doi: 10.1080/17843286.2018.1476115. Epub 2018 May 18.

PMID:
29774795
8.

Androgen and estrogen actions on male physical activity: a story beyond muscle.

Jardí F, Laurent MR, Dubois V, Kim N, Khalil R, Decallonne B, Vanderschueren D, Claessens F.

J Endocrinol. 2018 Jul;238(1):R31-R52. doi: 10.1530/JOE-18-0125. Epub 2018 May 9. Review.

PMID:
29743340
9.

Age-related changes in female mouse cortical bone microporosity.

Hemmatian H, Laurent MR, Bakker AD, Vanderschueren D, Klein-Nulend J, van Lenthe GH.

Bone. 2018 Aug;113:1-8. doi: 10.1016/j.bone.2018.05.003. Epub 2018 May 5.

PMID:
29738854
10.

Reassessing Free-Testosterone Calculation by Liquid Chromatography-Tandem Mass Spectrometry Direct Equilibrium Dialysis.

Fiers T, Wu F, Moghetti P, Vanderschueren D, Lapauw B, Kaufman JM.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2167-2174. doi: 10.1210/jc.2017-02360.

PMID:
29618085
11.

EAA clinical guideline on management of bone health in the andrological outpatient clinic.

Rochira V, Antonio L, Vanderschueren D.

Andrology. 2018 Mar;6(2):272-285. doi: 10.1111/andr.12470. Epub 2018 Mar 2. Review.

12.

Hypocalcemia after Denosumab in a Pulmonary Hypertension Patient Receiving Epoprostenol.

De Muynck B, Leys M, Cuypers J, Vanderschueren D, Delcroix M, Belge C.

Respiration. 2018;95(2):139-142. doi: 10.1159/000481713. Epub 2017 Oct 30.

13.

Testosterone boosts physical activity in male mice via dopaminergic pathways.

Jardí F, Laurent MR, Kim N, Khalil R, De Bundel D, Van Eeckhaut A, Van Helleputte L, Deboel L, Dubois V, Schollaert D, Decallonne B, Carmeliet G, Van den Bosch L, D'Hooge R, Claessens F, Vanderschueren D.

Sci Rep. 2018 Jan 17;8(1):957. doi: 10.1038/s41598-017-19104-0.

14.

Genetic Determinants of Circulating Estrogen Levels and Evidence of a Causal Effect of Estradiol on Bone Density in Men.

Eriksson AL, Perry JRB, Coviello AD, Delgado GE, Ferrucci L, Hoffman AR, Huhtaniemi IT, Ikram MA, Karlsson MK, Kleber ME, Laughlin GA, Liu Y, Lorentzon M, Lunetta KL, Mellström D, Murabito JM, Murray A, Nethander M, Nielson CM, Prokopenko I, Pye SR, Raffel LJ, Rivadeneira F, Srikanth P, Stolk L, Teumer A, Travison TG, Uitterlinden AG, Vaidya D, Vanderschueren D, Zmuda JM, März W, Orwoll ES, Ouyang P, Vandenput L, Wu FCW, de Jong FH, Bhasin S, Kiel DP, Ohlsson C.

J Clin Endocrinol Metab. 2018 Mar 1;103(3):991-1004. doi: 10.1210/jc.2017-02060. Erratum in: J Clin Endocrinol Metab. 2019 Jul 1;104(7):2580.

15.

Reproductive Hormone Levels Predict Changes in Frailty Status in Community-Dwelling Older Men: European Male Ageing Study Prospective Data.

Swiecicka A, Eendebak RJAH, Lunt M, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Slowikowska-Hilczer J, Lean MEJ, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FCW, Rutter MK; European Male Ageing Study Group.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):701-709. doi: 10.1210/jc.2017-01172.

16.

Elevated luteinizing hormone despite normal testosterone levels in older men-natural history, risk factors and clinical features.

Eendebak RJAH, Ahern T, Swiecicka A, Pye SR, O'Neill TW, Bartfai G, Casanueva FF, Maggi M, Forti G, Giwercman A, Han TS, Słowikowska-Hilczer J, Lean MEJ, Punab M, Pendleton N, Keevil BG, Vanderschueren D, Rutter MK, Tampubolon G, Goodacre R, Huhtaniemi IT, Wu FCW; EMAS Group.

Clin Endocrinol (Oxf). 2018 Mar;88(3):479-490. doi: 10.1111/cen.13524. Epub 2017 Dec 25.

PMID:
29178359
17.

Estradiol and Age-Related Bone Loss in Men.

Jardí F, Laurent MR, Claessens F, Vanderschueren D.

Physiol Rev. 2018 Jan 1;98(1):1. doi: 10.1152/physrev.00051.2017. No abstract available.

18.

Sex steroids and the kidney: role in renal calcium and phosphate handling.

Khalil R, Kim NR, Jardi F, Vanderschueren D, Claessens F, Decallonne B.

Mol Cell Endocrinol. 2018 Apr 15;465:61-72. doi: 10.1016/j.mce.2017.11.011. Epub 2017 Nov 16. Review.

PMID:
29155307
19.

Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.

De Smedt J, Van Kelst S, Boecxstaens V, Stas M, Bogaerts K, Vanderschueren D, Aura C, Vandenberghe K, Lambrechts D, Wolter P, Bechter O, Nikkels A, Strobbe T, Emri G, Marasigan V, Garmyn M.

BMC Cancer. 2017 Aug 23;17(1):562. doi: 10.1186/s12885-017-3538-4.

20.

Accuracy and reproducibility of mouse cortical bone microporosity as quantified by desktop microcomputed tomography.

Hemmatian H, Laurent MR, Ghazanfari S, Vanderschueren D, Bakker AD, Klein-Nulend J, van Lenthe GH.

PLoS One. 2017 Aug 10;12(8):e0182996. doi: 10.1371/journal.pone.0182996. eCollection 2017.

Supplemental Content

Loading ...
Support Center